ClinicalTrials.gg
CompletedNCT03188666LUMINA-1Updated Dec 2, 2022Results posted

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

A Phase 2 interventional study of REGN2477 and Matching placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Regeneron Pharmaceuticals. Completed at 11 sites in 8 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-12-02.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Myositis Ossificans with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Myositis Ossificans · United States.

Enrollment
10th of 12
44 · median 60
Started
2018
the only one that year
Phase 2
6 of 19
1 open now
Registered
7th of 19
by date
Lead sponsor
3 of 19
Regeneron Pharmaceuticals

Among the 19 studies in Myositis Ossificans with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2, and was the 7th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

4 of the 19 studies in Myositis Ossificans with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myositis Ossificans with a site in United States, or all of them as a file.
02

Study summary

This is a three period study design consisting of a 6-month, randomized, double-blind placebo-controlled treatment (period 1) followed by a 6-month, open-label treatment (period 2) and a follow-up treatment period (period 3).

Primary safety objective of the study is to assess the safety and tolerability of REGN2477 in male and female patients with fibrodysplasia ossificans progressiva (FOP).

Primary efficacy objective of the study is to assess the effect of REGN2477 versus placebo on the change from baseline in heterotopic ossification (HO) in patients with FOP, as determined by 18-NaF uptake in HO lesions by positron emission tomography (PET) and in total volume of HO lesions by computed tomography (CT).

Key Secondary objectives are:

  • To compare the effect of REGN2477 versus placebo on pain due to FOP, as measured by the area under the curve (AUC) for pain based on daily pain numeric rating scale (NRS) scores
  • To assess the effect of REGN2477 versus placebo on the change from baseline in HO, as determined by the number of new HO lesions identified by 18F-NaF PET or by CT
  • To assess the effect of REGN2477 versus placebo on the change from baseline in 18F-NaF standardized uptake value maximum (SUVmax) of individual active HO site(s) by PET
  • To assess the effect of REGN2477, between week 28 and week 56, on the number, activity, and volume of HO lesions identified by 18F-NaF PET or by CT in patients who switch from placebo to REGN2477 at week 28 versus the same patients between baseline and week 28
  • To assess the effect of REGN2477 versus placebo on the change from baseline in biochemical markers of bone formation
  • To characterize the concentrations of total activin A at baseline and over time following the first dose of study drug
  • To characterize the concentration-time profile (pharmacokinetics [PK]) of REGN2477 in patients with FOP
  • To assess the immunogenicity of REGN2477
03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and women 18 to 60 years of age at screening.
  • Clinical diagnosis of FOP (based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive heterotopic ossification (HO)).
  • Confirmation of FOP diagnosis with documentation of any ACVR1 mutation.
  • FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, and other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of heterotopic ossifications (increase in site or number of HO lesions) with/without being associated with flare-up episodes.
  • Willing and able to undergo PET and CT imaging procedures and other procedures as defined in this study.

Key Exclusion Criteria:

  • Significant concomitant illness or history of significant illness such as, but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study.
  • Previous history or diagnosis of cancer.
  • Use of bisphosphonate within 1 year of screening.
  • Concurrent participation in another interventional clinical study, or a non-interventional study with radiographic measures or invasive procedures (e.g. collection of blood or tissue samples). Participation in the FOP Connection Registry or other studies in which participants complete study questionnaires are allowed.
  • Treatment with another drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer.
  • Pregnant or breastfeeding women.
  • Male and women of participants who are unwilling to practice highly effective .

Note: Other protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    REGN2477

    Drug: REGN2477

  • Experimental
    Placebo

    Drug: Matching placebo

Interventions

  • Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.

  • DrugMatching placebo

    Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.

06

What researchers measure

Primary outcomes

  1. Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    Treatment-emergent adverse events (TEAEs) are adverse events not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious TEAE was defined as any untoward medical occurrence that resulted in any of following outcomes not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. Number of participants with TEAEs and Serious TEAEs are reported.

    Time frame: Up to Week 28

  2. Period 1: Number of Participants With TEAEs by Severity

    Severity of TEAEs were graded as follows: Mild: Does not interfere in a significant manner with the participant's normal functioning level. It may be an annoyance. Prescription drugs are not ordinarily needed for relief of symptoms but may be given because of personality of the participants. Moderate: Produces some impairment of functioning but is not hazardous to health. It was uncomfortable or an embarrassment. Treatment for symptom may be needed. Severe: Produces significant impairment of functioning or incapacitation and was a definite hazard to the participant's health. Treatment for symptom may be given and/or participants hospitalized. Number of participants with TEAEs by severity is reported.

    Time frame: Up to Week 28

  3. Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO)

    18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (standardized area under the curve \[AUC\]) of the percent change from baseline in total lesion activity by 18\^F-NaF PET up to Week 28 in AHO analysis set is reported.

    Time frame: Baseline and Week 28

  4. Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT during Period 1 at Week 28 is reported.

    Time frame: Week 28

  5. Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. HO detectable by CT that developed after baseline are referred to as "new HO lesions." Number of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan is reported.

    Time frame: Week 28, Week 56

  6. Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC)

    18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (Standardized AUC) of the percent change from baseline in total lesion activity as assessed by 18\^F-NaF PET in Active HO Classic ACVR1 Mutation (AHOC) analysis set up to Week 28 is reported.

    Time frame: Week 28

  7. Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions was assessed by CT at Week 28 in AHOC analysis set is reported.

    Time frame: Week 28

Secondary outcomes

  1. Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO)

    The pain NRS is a patient reported outcome (PRO) used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-weighted average (Standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHO analysis set is reported.

    Time frame: Week 28

  2. Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC)

    The pain NRS is a PRO used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-Weighted average (standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHOC analysis set is reported.

    Time frame: Week 28

  3. Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC)

    Standardized uptake value max (SUVmax) was a measurement of the maximum radiopharmaceutical uptake within the volume of interest. Relative accuracy of a particular radiotracer in a particular tissue is determined by expressing the absolute accuracy (obtained in the primary outcome measure) in terms of percent difference between SUVmax values obtained from PET/CT. Percent Change in 18\^F-NaF SUVmax of Individual Active HO Site(s) assessed by 18\^F-NaF PET in AHOC analysis set is reported.

    Time frame: Week 8

  4. Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO)

    Percent change in 18\^F-NaF SUVmax of individual active HO site(s) as assessed by 18\^F-NaF PET at Week 8 in AHO analysis set is reported.

    Time frame: Week 8

  5. Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC)

    Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET at Week 28 in AHOC analysis set is reported.

    Time frame: Week 28

  6. Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO)

    Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET in AHO analysis set is reported.

    Time frame: Week 28

  7. Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions was detectable by CT using AHOC analysis set is reported.

    Time frame: Week 28

  8. Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions detectable by CT at Week 28 in AHO analysis set is reported.

    Time frame: Week 28

  9. Period 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    Number of new HO lesions as assessed by 18\^F-NaF PET at Week 56 Relative to Week 28 Scan is reported.

    Time frame: Week 28, Week 56

  10. Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to week 28 scan is reported.

    Time frame: Week 28, Week 56

  11. Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to week 28 scan is reported.

    Time frame: Week 28, Week 56

  12. Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to positron-emission tomography (PET). Number of new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.

    Time frame: Week 28, Week 56

  13. Period 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET). Percentage of participants with new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.

    Time frame: Week 28, Week 56

  14. Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

    18\^F-NaF PET is used to assess lesion and disease activity. Difference of Change from Week 28 to Week 56 as assessed by 18\^F-NaF PET versus from Baseline to Week 28

    Time frame: Week 28, Week 56

  15. Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Change from Week 28 to Week 56 as assessed by CT Scan versus from Baseline to Week 28 is reported

    Time frame: Week 28, Week 56

  16. Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Number of new HO lesions as assessed by CT at week 56 relative to baseline.

    Time frame: Baseline, Week 56

  17. Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Number of new HO lesions as assessed by CT only at week 56 relative baseline is reported.

    Time frame: Week 56

  18. Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to baseline were reported.

    Time frame: Week 56

  19. Period 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    18\^F-NaF PET is used to assess lesion and disease activity. Number of new HO lesions as assessed by 18\^F-NAF PET at week 56 relative to baseline is reported.

    Time frame: Week 56

  20. Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to baseline.

    Time frame: Week 56

  21. Period 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Total volume of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan.

    Time frame: Week 28, Week 56

  22. Period 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

    TLA is a measure of participant-level cumulative burden of metabolically active HO. Activity of individual HO lesions was calculated as the product of mean standard uptake value (SUVmean) and the PET volume of the active HO lesion. TLA was derived for each participant at each time point as the sum of HO lesion activity of individual target and new active HO lesions.

    Time frame: Week 28, Week 56

  23. Period 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

    Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported

    Time frame: Week 28, Week 56

  24. Period 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported.

    Time frame: Week 28, Week 56

  25. Period 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    Total Lesion Activity (TLA) is a measure of participant-level cumulative burden of metabolically active HO. TLA in New (Relative to Baseline) Lesions at Week 56 is reported.

    Time frame: Week 56

  26. Period 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Total volume of new HO lesions as assessed by CT only at week 56 relative to baseline is reported.

    Time frame: Week 56

  27. Period 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT)

    Percent change from baseline in TLA as assessed by 18\^F-NaF PET to week 56 were reported.

    Time frame: Week 56

  28. Period 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT)

    CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT to Week 56 were reported.

    Time frame: Week 56

  29. Period 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT)

    Percent Change from Week 28 to Week 56 is reported.

    Time frame: Week 28 to Week 56

  30. Period 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT)

    Percent change from baseline in 18\^F-NaF PET SUVmax to week 56

    Time frame: Baseline, Week 56

  31. Period 2: Daily Average Pain Due to FOP Measured Using the Daily NRS

    The pain NRS is a patient reported outcome used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome.

    Time frame: Week 28 up to Week 56

  32. Period 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary

    Percentage of participants with flare-ups starting between week 28 and week 56 as assessed by participant E-diary is reported.

    Time frame: Week 28 to Week 56

  33. Period 2: Percentage of Participants With Investigator-assessed Flare-ups

    Percentage of participants with investigator-assessed flare-ups were reported.

    Time frame: Week 28 to Week 56

  34. Periods 1, 2, and 3: Concentration of Total Activin A in Serum

    Concentration of total activin A in serum over time is reported.

    Time frame: Week 28, Week 56, Week 76

  35. Periods 1, 2, and 3: Concentrations of Functional REGN2477 in Serum

    Concentrations of REGN2477 capable of target binding were measured (functional drug).

    Time frame: Week 28, Week 56, Week 76

  36. Periods 1, 2, and 3: Number of Participants With Clinical Impact of Treatment-Emergent Anti-drug Antibodies (ADA) to REGN2477

    Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, \>= 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REGN2477 ADA assay post first dose when baseline results = negative or missing.

    Time frame: Up to Week 76

07

Results

Posted Dec 2, 2022

Participant flow

A total of 48 participants were screened, out of which, 44 participants were randomized and treated.

Period 1 (28 Weeks Double-blind)
Participant flow — Period 1 (28 Weeks Double-blind)
MilestonePlaceboREGN2477 10 mg/kg Q4WPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Started242000
Completed241900
Not completed0100
Withdrew: Adverse event0100
Period 2 (28 Weeks Open-label)
Participant flow — Period 2 (28 Weeks Open-label)
MilestonePlaceboREGN2477 10 mg/kg Q4WPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Started002419
Completed002418
Not completed0001
Withdrew: Death0001
Period 3 (20 Weeks Follow-up)
Participant flow — Period 3 (20 Weeks Follow-up)
MilestonePlaceboREGN2477 10 mg/kg Q4WPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Started002418
Completed002116
Not completed0032
Withdrew: Withdrawal by subject0020
Withdrew: Death0012

Outcome measures

PrimaryPeriod 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

Treatment-emergent adverse events (TEAEs) are adverse events not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious TEAE was defined as any untoward medical occurrence that resulted in any of following outcomes not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. Number of participants with TEAEs and Serious TEAEs are reported.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Period 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPlaceboREGN2477 10 mg/kg Q4W
Participants with at least one TEAE2420
Participants with at least one serious TEAE24
PrimaryPeriod 1: Number of Participants With TEAEs by Severity

Severity of TEAEs were graded as follows: Mild: Does not interfere in a significant manner with the participant's normal functioning level. It may be an annoyance. Prescription drugs are not ordinarily needed for relief of symptoms but may be given because of personality of the participants. Moderate: Produces some impairment of functioning but is not hazardous to health. It was uncomfortable or an embarrassment. Treatment for symptom may be needed. Severe: Produces significant impairment of functioning or incapacitation and was a definite hazard to the participant's health. Treatment for symptom may be given and/or participants hospitalized. Number of participants with TEAEs by severity is reported.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Period 1: Number of Participants With TEAEs by Severity
ParticipantsPlaceboREGN2477 10 mg/kg Q4W
Participants with at least one Mild TEAE97
Participants with at least one Moderate TEAE1210
Participants with at least one Severe TEAE33
PrimaryPeriod 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO)

18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (standardized area under the curve \[AUC\]) of the percent change from baseline in total lesion activity by 18\^F-NaF PET up to Week 28 in AHO analysis set is reported.

Time frame:
Baseline and Week 28
Reported as:
Least squares mean · Percent Change
Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Time-Weighted Average (Standardized Area Under the Curve [AUC]) of the Percent Change From Baseline in Total Lesion Activity by Fluorine-18-labeled Sodium Fluoride (18^F-NaF) Positron Emission Tomography (PET) at Week 28 (AHO)16.6 ± 9.11-8.1 ± 9.93
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · ANCOVA · p = 0.0741 · Least square mean difference: -24.6 · 95% CI -51.8 to 2.5
PrimaryPeriod 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT during Period 1 at Week 28 is reported.

Time frame:
Week 28
Reported as:
Least squares mean · Percent Change
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28 (AHO)32.0 ± 18.667.1 ± 20.43
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · Mixed Model with Repeated Measure (MMRM) · p = 0.3726 · Least square mean difference: -24.9 · 95% CI -80.8 to 30.9
PrimaryPeriod 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. HO detectable by CT that developed after baseline are referred to as "new HO lesions." Number of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · New HO Lesions
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
New HO LesionsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)0
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.0039 (Week 56 vs. Week 28)
PrimaryPeriod 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC)

18\^F-NaF PET is used to assess lesion and disease activity. Time-weighted average (Standardized AUC) of the percent change from baseline in total lesion activity as assessed by 18\^F-NaF PET in Active HO Classic ACVR1 Mutation (AHOC) analysis set up to Week 28 is reported.

Time frame:
Week 28
Reported as:
Least squares mean · Percent Change
Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Time-weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity Assessed by 18^F-NaF PET at Week 28 (AHOC)17.6 ± 9.73-8.0 ± 10.14
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · ANCOVA · p = 0.0756 · Least square mean difference: -25.6 · 95% CI -53.9 to 2.8
PrimaryPeriod 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions was assessed by CT at Week 28 in AHOC analysis set is reported.

Time frame:
Week 28
Reported as:
Least squares mean · Percent Change
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT at Week 28 (AHOC)34.9 ± 19.907.0 ± 20.87
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · Mixed Model with Repeated Measure (MMRM) · p = 0.3407 · Least square mean difference: -27.8 · 95% CI -86.1 to 30.5
SecondaryPeriod 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO)

The pain NRS is a patient reported outcome (PRO) used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-weighted average (Standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHO analysis set is reported.

Time frame:
Week 28
Reported as:
Least squares mean · Score on a Scale
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO)
Score on a ScalePlaceboREGN2477 10 mg/kg Q4W
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to Fibrodysplasia Ossificans Progressiva (FOP) Assessed by Daily Numeric Rating Scale (NRS) at Week 28 (AHO)-0.17 ± 0.205-0.51 ± 0.231
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · ANCOVA · p = 0.2656 · Least square mean difference: -0.34 · 95% CI -0.96 to 0.27
SecondaryPeriod 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC)

The pain NRS is a PRO used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome. Time-Weighted average (standardized AUC) of the change from baseline in daily pain due to FOP assessed by daily NRS at Week 28 in AHOC analysis set is reported.

Time frame:
Week 28
Reported as:
Least squares mean · Score on a Scale
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC)
Score on a ScalePlaceboREGN2477 10 mg/kg Q4W
Period 1: Time-weighted Average (Standardized AUC) of the Change From Baseline in Daily Pain Due to FOP, Assessed by Daily NRS at Week 28 (AHOC)-0.12 ± 0.221-0.48 ± 0.237
Statistical analysis
  • Placebo vs REGN2477 10 mg/kg Q4W · ANCOVA · p = 0.2651 · Least square mean difference: -0.36 · 95% CI -1.01 to 0.29
SecondaryPeriod 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC)

Standardized uptake value max (SUVmax) was a measurement of the maximum radiopharmaceutical uptake within the volume of interest. Relative accuracy of a particular radiotracer in a particular tissue is determined by expressing the absolute accuracy (obtained in the primary outcome measure) in terms of percent difference between SUVmax values obtained from PET/CT. Percent Change in 18\^F-NaF SUVmax of Individual Active HO Site(s) assessed by 18\^F-NaF PET in AHOC analysis set is reported.

Time frame:
Week 8
Reported as:
Mean · Percent Change
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) Assessed by 18^F-NaF PET at Week 8 (AHOC)-6.7 ± 28.79-21.6 ± 30.25
SecondaryPeriod 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO)

Percent change in 18\^F-NaF SUVmax of individual active HO site(s) as assessed by 18\^F-NaF PET at Week 8 in AHO analysis set is reported.

Time frame:
Week 8
Reported as:
Mean · Percent Change
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO)
Percent ChangePlaceboREGN2477 10 mg/kg Q4W
Period 1: Percent Change From Baseline in 18^F-NaF SUVmax of Individual Active HO Site(s) as Assessed by 18^F-NaFPET at Week 8 (AHO)-7.9 ± 28.80-21.6 ± 30.25
SecondaryPeriod 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC)

Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET at Week 28 in AHOC analysis set is reported.

Time frame:
Week 28
Reported as:
Mean · HO Lesions
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC)
HO LesionsPlaceboREGN2477 10 mg/kg Q4W
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHOC)-1.0 ± 2.66-2.3 ± 2.24
SecondaryPeriod 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO)

Change from baseline in number of HO lesions was assessed by 18\^F-NaF PET in AHO analysis set is reported.

Time frame:
Week 28
Reported as:
Mean · HO Lesions
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO)
HO LesionsPlaceboREGN2477 10 mg/kg Q4W
Period 1: Change From Baseline in Number of HO Lesions as Assessed by 18^F-NaF PET at Week 28 (AHO)-1.0 ± 2.59-2.3 ± 2.24
SecondaryPeriod 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions was detectable by CT using AHOC analysis set is reported.

Time frame:
Week 28
Reported as:
Mean · HO Lesions
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC)
HO LesionsPlaceboREGN2477 10 mg/kg Q4W
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHOC)1.2 ± 2.00-0.3 ± 1.34
SecondaryPeriod 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Change from baseline in number of HO lesions detectable by CT at Week 28 in AHO analysis set is reported.

Time frame:
Week 28
Reported as:
Mean · HO Lesions
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO)
HO LesionsPlaceboREGN2477 10 mg/kg Q4W
Period 1: Change From Baseline in Number of HO Lesions Detectable by CT at Week 28 (AHO)1.2 ± 1.93-0.3 ± 1.34
SecondaryPeriod 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

Number of new HO lesions as assessed by 18\^F-NaF PET at Week 56 Relative to Week 28 Scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · New HO lesions
Period 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
New HO lesionsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)1
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.0039 (Week 56 vs. Week 28)
SecondaryPeriod 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to week 28 scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
Percentage of ParticipantsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)0.0
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · McNemar · p = 0.0027 (Week 56 vs. Week 28)
SecondaryPeriod 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to week 28 scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
Percentage of ParticipantsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)4.5
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · McNemar · p = 0.0047 (Week 56 vs. Week 28)
SecondaryPeriod 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to positron-emission tomography (PET). Number of new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · New HO lesions
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
New HO lesionsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)3
SecondaryPeriod 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET). Percentage of participants with new HO lesions as assessed by CT only at week 56 relative to week 28 scan is reported.

Time frame:
Week 28, Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
Percentage of ParticipantsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT Only at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)9.1
SecondaryPeriod 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

18\^F-NaF PET is used to assess lesion and disease activity. Difference of Change from Week 28 to Week 56 as assessed by 18\^F-NaF PET versus from Baseline to Week 28

Time frame:
Week 28, Week 56
Reported as:
Mean · Active lesions
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
Active lesionsPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)-1.2 ± 4.311.3 ± 3.26
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W vs REGN2477/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.3663 (Period 2 vs. Period 1)
SecondaryPeriod 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Change from Week 28 to Week 56 as assessed by CT Scan versus from Baseline to Week 28 is reported

Time frame:
Week 28, Week 56
Reported as:
Mean · Active lesions
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
Active lesionsPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Period 2 vs. Period 1: Change From Week 28 in Number of Active HO Lesions as Assessed by CT Scan at Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)-1.3 ± 2.400.3 ± 1.24
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W vs REGN2477/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.0010 (Period 2 vs. Period 1)
SecondaryPeriod 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Number of new HO lesions as assessed by CT at week 56 relative to baseline.

Time frame:
Baseline, Week 56
Reported as:
Number · New HO Lesions
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)
New HO LesionsREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)2
SecondaryPeriod 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Number of new HO lesions as assessed by CT only at week 56 relative baseline is reported.

Time frame:
Week 56
Reported as:
Number · New HO Lesions
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)
New HO LesionsREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)1
SecondaryPeriod 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percentage of participants with new HO lesions as assessed by CT at week 56 relative to baseline were reported.

Time frame:
Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)
Percentage of ParticipantsREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With New HO Lesions as Assessed by CT at Week 56 Relative to Baseline (AHO COVID-19 mITT)11.1
SecondaryPeriod 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

18\^F-NaF PET is used to assess lesion and disease activity. Number of new HO lesions as assessed by 18\^F-NAF PET at week 56 relative to baseline is reported.

Time frame:
Week 56
Reported as:
Number · New HO Lesions
Period 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
New HO LesionsREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Number of New HO Lesions as Assessed by 18^F-NAF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)1
SecondaryPeriod 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

18\^F-NaF PET is used to assess lesion and disease activity. Percentage of participants with new HO lesions as assessed by 18\^F-NaF PET at week 56 relative to baseline.

Time frame:
Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
Percentage of ParticipantsREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)5.6
SecondaryPeriod 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Total volume of new HO lesions as assessed by CT at Week 56 relative to Week 28 scan.

Time frame:
Week 28, Week 56
Reported as:
Mean · cubic centimeter (cm^3)
Period 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
cubic centimeter (cm^3)Placebo/REGN2477 10 mg/kg Q4W
Period 2: Total Volume of New HO Lesions as Assessed by CT at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)0.0 ± 0.21
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.0039 (Week 56 vs. Week 28)
SecondaryPeriod 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)

TLA is a measure of participant-level cumulative burden of metabolically active HO. Activity of individual HO lesions was calculated as the product of mean standard uptake value (SUVmean) and the PET volume of the active HO lesion. TLA was derived for each participant at each time point as the sum of HO lesion activity of individual target and new active HO lesions.

Time frame:
Week 28, Week 56
Reported as:
Mean · gram (g)
Period 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)
gram (g)Placebo/REGN2477 10 mg/kg Q4W
Period 2: Total Lesion Activity (TLA) Assessed by 18^F-NaF PET in New HO Lesions at Week 56 Relative to Week 28 Scan (AHO COVID-19 mITT)13.2 ± 61.89
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.0273 (Week 56 vs. Week 28)
SecondaryPeriod 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported

Time frame:
Week 28, Week 56
Reported as:
Mean · Percent Change
Period 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
Percent ChangePlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Period 2 vs. Period 1: Percent Change From Week 28 in TLA as Assessed by 18^F-NaF PET to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)-66.9 ± 181.0614.0 ± 41.17
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W vs REGN2477/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.2123 (Period 2 vs. Period 1)
SecondaryPeriod 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Difference of Percent Change from Week 28 to Week 56 versus from Baseline to Week 28 is reported.

Time frame:
Week 28, Week 56
Reported as:
Mean · Percent Change
Period 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)
Percent ChangePlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Period 2 vs. Period 1: Percent Change From Week 28 in the Total Volume of HO Lesions as Assessed by CT to Week 56 (Period 2) Versus the Same Participants Between Baseline and Week 28 (Period 1) (AHO COVID-19 mITT)-31.8 ± 132.47-11.1 ± 24.07
Statistical analysis
  • Placebo/REGN2477 10 mg/kg Q4W vs REGN2477/REGN2477 10 mg/kg Q4W · Wilcoxon signed rank test · p = 0.1528 (Period 2 vs. Period 1)
SecondaryPeriod 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)

Total Lesion Activity (TLA) is a measure of participant-level cumulative burden of metabolically active HO. TLA in New (Relative to Baseline) Lesions at Week 56 is reported.

Time frame:
Week 56
Reported as:
Mean · gram (g)
Period 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)
gram (g)REGN2477/ REGN2477
Period 2: TLA in New HO Lesions as Assessed by 18^F-NaF PET at Week 56 Relative to Baseline (AHO COVID-19 mITT)0.7 ± 2.13
SecondaryPeriod 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT Only: Computed Tomography (CT) assessment without reference to Positron-Emission Tomography (PET); Total volume of new HO lesions as assessed by CT only at week 56 relative to baseline is reported.

Time frame:
Week 56
Reported as:
Mean · cubic centimeter (cm^3)
Period 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)
cubic centimeter (cm^3)REGN2477/REGN2477 10 mg/kg Q4W
Period 2: Total Volume of New HO Lesions as Assessed by CT Only at Week 56 Relative to Baseline (AHO COVID-19 mITT)0.0 ± 0.02
SecondaryPeriod 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT)

Percent change from baseline in TLA as assessed by 18\^F-NaF PET to week 56 were reported.

Time frame:
Week 56
Reported as:
Mean · Percent Change
Period 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT)
Percent ChangeREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Percent Change From Baseline in TLA as Assessed by 18^F-NaF PET to Week 56 (AHO COVID-19 mITT)-16.4 ± 53.10
SecondaryPeriod 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT)

CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue, and blood vessels. CT scan acquired contemporaneously to the PET scan. Percent change from baseline in the total volume of HO lesions as assessed by CT to Week 56 were reported.

Time frame:
Week 56
Reported as:
Mean · Percent Change
Period 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT)
Percent ChangeREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by CT to Week 56 (AHO COVID-19 mITT)2.6 ± 10.18
SecondaryPeriod 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT)

Percent Change from Week 28 to Week 56 is reported.

Time frame:
Week 28 to Week 56
Reported as:
Mean · Percent Change
Period 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT)
Percent ChangePlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percent Change From Week 28 in SUVmax as Assessed by 18^F-NaF to Week 56 (AHO COVID-19 mITT)-30.3 ± 15.03
SecondaryPeriod 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT)

Percent change from baseline in 18\^F-NaF PET SUVmax to week 56

Time frame:
Baseline, Week 56
Reported as:
Mean · Percent Change
Period 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT)
Percent ChangeREGN2477/REGN2477 10 mg/kg Q4W
Period 2: Percent Change From Baseline in 18^F-NaF PET SUVmax to Week 56 (AHO COVID-19 mITT)-41.9 ± 29.16
SecondaryPeriod 2: Daily Average Pain Due to FOP Measured Using the Daily NRS

The pain NRS is a patient reported outcome used by participants to rate their pain associated with FOP. Participants were asked to rate their pain on a scale that ranges from "0" (no pain) to "10" (worst possible pain), where the highest score indicated worst outcome.

Time frame:
Week 28 up to Week 56
Reported as:
Mean · Score on a Scale
Period 2: Daily Average Pain Due to FOP Measured Using the Daily NRS
Score on a ScalePlacebo/REGN2477 10 mg/kg Q4W
Period 2: Daily Average Pain Due to FOP Measured Using the Daily NRS1.60 ± 1.969
SecondaryPeriod 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary

Percentage of participants with flare-ups starting between week 28 and week 56 as assessed by participant E-diary is reported.

Time frame:
Week 28 to Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary
Percentage of ParticipantsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With Flare-ups Assessed by Participant E-diary13.6
SecondaryPeriod 2: Percentage of Participants With Investigator-assessed Flare-ups

Percentage of participants with investigator-assessed flare-ups were reported.

Time frame:
Week 28 to Week 56
Reported as:
Number · Percentage of Participants
Period 2: Percentage of Participants With Investigator-assessed Flare-ups
Percentage of ParticipantsPlacebo/REGN2477 10 mg/kg Q4W
Period 2: Percentage of Participants With Investigator-assessed Flare-ups13.6
SecondaryPeriods 1, 2, and 3: Concentration of Total Activin A in Serum

Concentration of total activin A in serum over time is reported.

Time frame:
Week 28, Week 56, Week 76
Reported as:
Mean · milligram per Liter (mg/L)
Periods 1, 2, and 3: Concentration of Total Activin A in Serum
milligram per Liter (mg/L)Placebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
Week 280.0000813 ± 0.0001640.0537 ± 0.0116
Week 560.0563 ± 0.01720.0503 ± 0.0113
Week 760.0487 ± 0.01920.0497 ± 0.0176
SecondaryPeriods 1, 2, and 3: Concentrations of Functional REGN2477 in Serum

Concentrations of REGN2477 capable of target binding were measured (functional drug).

Time frame:
Week 28, Week 56, Week 76
Reported as:
Mean · mg/L
Periods 1, 2, and 3: Concentrations of Functional REGN2477 in Serum
mg/LPlacebo/REGN2477 10 mg/kg Q4WREGN2477 10 mg/kg Q4W
Week 280 ± 0130 ± 46.6
Week 56100 ± 27.3122 ± 54.8
Week 76113 ± 27.0113 ± 23.0
SecondaryPeriods 1, 2, and 3: Number of Participants With Clinical Impact of Treatment-Emergent Anti-drug Antibodies (ADA) to REGN2477

Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses \< 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, \>= 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REGN2477 ADA assay post first dose when baseline results = negative or missing.

Time frame:
Up to Week 76
Reported as:
Count of participants · Participants
Periods 1, 2, and 3: Number of Participants With Clinical Impact of Treatment-Emergent Anti-drug Antibodies (ADA) to REGN2477
ParticipantsPlacebo/REGN2477 10 mg/kg Q4WREGN2477/ REGN2477
Negative2418
Pre-existing Immunoreactivity00
Treatment-Boosted Response00
Treatment-Emergent Response01

Adverse events

Collected over From first dose of study drug to end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)2/24 (8.3%)24/24 (100%)
REGN2477 10 mg/kg Q4W0/20 (0%)4/20 (20%)20/20 (100%)
Placebo/REGN2477 10 mg/kg Q4W2/24 (8.3%)6/24 (25%)24/24 (100%)
REGN2477/REGN2477 10 mg/kg Q4W3/19 (15.8%)7/19 (36.8%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlaceboREGN2477 10 mg/kg Q4WPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
PneumoniaInfections and infestations0/241/200/241/19
AbscessInfections and infestations0/240/200/241/19
Perirectal abscessInfections and infestations0/240/200/241/19
Respiratory tract infection viralInfections and infestations0/240/200/241/19
Subcutaneous abscessInfections and infestations0/240/200/241/19
Intestinal obstructionGastrointestinal disorders0/241/200/241/19
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/240/200/241/19
PyrexiaGeneral disorders0/240/201/241/19
Head injuryInjury, poisoning and procedural complications0/240/200/241/19
Cerebrovascular accidentNervous system disorders0/240/200/241/19
Most frequent other events
Showing 10 of 225
Most frequent other events
EventPlaceboREGN2477 10 mg/kg Q4WPlacebo/REGN2477 10 mg/kg Q4WREGN2477/REGN2477 10 mg/kg Q4W
MadarosisSkin and subcutaneous tissue disorders0/246/2013/248/19
HeadacheNervous system disorders7/2410/206/248/19
AcneSkin and subcutaneous tissue disorders3/246/2012/244/19
EpistaxisRespiratory, thoracic and mediastinal disorders4/2410/2010/245/19
ArthralgiaMusculoskeletal and connective tissue disorders9/247/208/249/19
NasopharyngitisInfections and infestations5/243/205/249/19
Pain in extremityMusculoskeletal and connective tissue disorders9/245/206/248/19
PyrexiaGeneral disorders0/243/205/247/19
Back painMusculoskeletal and connective tissue disorders1/244/207/246/19
DiarrhoeaGastrointestinal disorders6/245/205/242/19

Baseline characteristics

The full analysis set (FAS) included all randomized participants and was based on the treatment allocated.

Age, Continuous
Age, Continuous(Years)PlaceboREGN2477 10 mg/kg Q4WTotal
Mean27.8 ± 8.5427.3 ± 8.6727.6 ± 8.50
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboREGN2477 10 mg/kg Q4WTotal
Female141125
Male10919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboREGN2477 10 mg/kg Q4WTotal
Hispanic or Latino000
Not Hispanic or Latino242044
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboREGN2477 10 mg/kg Q4WTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American101
White221739
More than one race000
Unknown or Not Reported011
Total Lesion Activity by fluorine-18 sodium fluoride (18 F-NaF) PET (AHO Analysis Set)
Total Lesion Activity by fluorine-18 sodium fluoride (18 F-NaF) PET (AHO Analysis Set)(gram (g))PlaceboREGN2477 10 mg/kg Q4WTotal
Mean473.40 ± 348.373418.18 ± 372.801448.30 ± 356.510
Total Volume of HO Lesions as Assessed by Computed Tomography (CT) (AHO Analysis Set)
Total Volume of HO Lesions as Assessed by Computed Tomography (CT) (AHO Analysis Set)(cubic centimeter (cm^3))PlaceboREGN2477 10 mg/kg Q4WTotal
Mean235.78 ± 253.329251.43 ± 327.881242.89 ± 286.167
Total Lesion Activity by 18F-NaF PET (AHOC Analysis Set)
Total Lesion Activity by 18F-NaF PET (AHOC Analysis Set)(gram (g))PlaceboREGN2477 10 mg/kg Q4WTotal
Mean464.27 ± 350.479418.18 ± 372.801442.32 ± 357.581
Total Volume of HO Lesions as Assessed by CT (AHOC Analysis Set)
Total Volume of HO Lesions as Assessed by CT (AHOC Analysis Set)(cubic centimeter (cm^3))PlaceboREGN2477 10 mg/kg Q4WTotal
Mean239.72 ± 263.813251.43 ± 327.881245.29 ± 292.408

1 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University
    Nashville, Tennessee 37240, United States
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Hopital Cochin
    Paris, 75014, France
  • Hopital Lariboisiere,Hospitalier Universitaire Nord
    Paris, 751010, France
  • Giannina Gaslini Institute
    Genova, 16147, Italy
  • VU University Medical Center
    Amsterdam, North Holland 1081 HV, Netherlands
  • Szpital Wojewodzki Nr 2
    Rzeszow, 35-301, Poland
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Royal National Orthopaedic Hospital, Brockley Hill
    Stanmore, Middlesex HA7 4LP, United Kingdom
09

References and documents

Publications

  • Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y, DelGizzi R, Forleo-Neto E, Rajadhyaksha M, Herman G, Davis JD. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study. J Clin Pharmacol. 2020 Nov;60(11):1424-1431. doi: 10.1002/jcph.1638. Epub 2020 Jun 18. PubMed 32557665 ↗
  • Aykul S, Corpina RA, Goebel EJ, Cunanan CJ, Dimitriou A, Kim HJ, Zhang Q, Rafique A, Leidich R, Wang X, McClain J, Jimenez J, Nannuru KC, Rothman NJ, Lees-Shepard JB, Martinez-Hackert E, Murphy AJ, Thompson TB, Economides AN, Idone V. Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop. Elife. 2020 Jun 9;9:e54582. doi: 10.7554/eLife.54582. PubMed 32515349 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Sep 2019, 18 months.

Results were first posted in Dec 2022, 3 years 2 months after primary completion. A results delay was requested in Sep 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 15, 2017
StartActual
Feb 26, 2018
Primary completionActual
Sep 16, 2019
CompletionActual
Sep 16, 2021
Results delay requested
Sep 15, 2020
Results first posted
Dec 2, 2022
Last update
Dec 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03188666
Responsible party
Sponsor
First posted
Jun 15, 2017
Start date
Feb 26, 2018
Primary completion
Sep 16, 2019
Completion
Sep 16, 2021
Results posted
Dec 2, 2022
Last update
Dec 2, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garetosmab

Start the discussion